Edwards Lifesciences (NYSE:EW) VP Sells $2,000,190.90 in Stock

Posted by Brenda Bartman on May 30th, 2026

Edwards Lifesciences Corporation (NYSE:EW – Get Free Report) VP Donald Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $86.41 on Friday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $49.76 billion, a P/E ratio of 45.96, a PEG ratio of 2.15 and a beta of 0.87. The stock’s 50 day moving average is $81.73 and its 200 day moving average is $83.01. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $88.28.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on EW. BTIG Research upped their target price on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. Piper Sandler reissued an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Evercore reiterated an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Robert W. Baird increased their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Finally, Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a research note on Wednesday, April 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.65.

Read Our Latest Stock Report on Edwards Lifesciences

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently added to or reduced their stakes in EW. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Edwards Lifesciences by 13.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after purchasing an additional 10,078 shares during the period. Atlantic Union Bankshares Corp grew its stake in shares of Edwards Lifesciences by 2,240.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after purchasing an additional 11,384 shares during the period. Washington Trust Advisors Inc. grew its stake in shares of Edwards Lifesciences by 15.6% during the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after purchasing an additional 17,625 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares during the period. Finally, Azzad Asset Management Inc. ADV grew its stake in shares of Edwards Lifesciences by 330.5% during the 3rd quarter. Azzad Asset Management Inc. ADV now owns 21,227 shares of the medical research company’s stock valued at $1,651,000 after purchasing an additional 16,296 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

(Get Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.